BioNTech SE exceeded earnings expectations with strong oncology pipeline development, despite reduced vaccine revenue.

In a report released today, Terence Flynn from Morgan Stanley maintained a Buy rating on BioNTech SE (BNTX – Research Report), with a price ...

"We expect 2025 to be a data-rich year with multiple important updates from our priority programs," said Chief Executive Ugur Sahin. BioNTech forecast revenue between 1.7 billion euros and 2.2 billion ...

German COVID-19 vaccine maker BioNTech on Monday said that its 2025 revenues would likely fall to between 1.7 billion euros ...

The full audited consolidated financial statements as of and for the year ended December 31, 2024, can be found in BioNTech's Annual Report on Form 20-F filed today with the United States Securities ...

BioNTech has slipped into the red in the development of cancer drugs. The company, which is known for its coronavirus vaccine, now wants to cut jobs.

The benchmark US stock measures were trending lower before Monday's opening bell as traders await fresh inflation data later in the week. Standard & Poor's 500 declined 1.1%, the Dow Jones Industrial ...

EDT BioNTech (BNTX) sees FY25 CapEx EUR 250M-EUR 350MDiscover the Best Stocks and Maximize Your Portfolio: See what stocks are receiving ...

US stock futures dropped as investors brace for key inflation reports and react to President Trump's renewed tariff threats.

Wall Street expects BioNTech SE BNTX to report quarterly earnings at 58 cents per share on revenue of $1.15 billion before ...

A dovish consumer price index could cement a June Fed cut. Adobe set to report earnings. DOJ still wants to break up Google.